Informazioni sul prodotto
Prasugrel is a prodrug that is metabolized to its active form, the prasugrel metabolite (PMS), which inhibits the ADP-induced platelet activation and aggregation. The PMS has been extensively studied in clinical trials and has shown to be effective in reducing cardiovascular events. The lc-ms/ms method has been used to measure the levels of PMS in human serum samples. Significant interactions have been observed with pharmacological agents such as clopidogrel, diazepam, erythromycin, and warfarin; however, these interactions are not clinically relevant as they do not lead to an increase in adverse effects. The matrix effect is observed due to the variability in plasma concentrations of PMS based on dosage and concentration of other drugs taken simultaneously. Prasugrel also affects the pharmacokinetic properties of other drugs taken concurrently due to its inhibition of CYP2C19 activity.
